2011-37: RPE-choroid graft for age-related macular degeneration. A patient registry.
Standard treatment for patients with exudative age-related macular degeneration (AMD) is intravitreal injection of anti-VEGF. There are patients for whom this therapy does not help to improve prospects, but since alternative therapies are not available, these patients are initially treated with anti-VEGF. Recently it has been shown that a retinal pigment epithelium (RPE)-choroid graft translocation in the treatment of patients with choroidal neovascular lesions of AMD (who do not respond to anti-VEGF) can stabilize or even improve visual acuity. This prospective observational patient registry study allows us to systematically evaluate the clinical outcomes of this type of treatment and, furthermore, to assess the potential of newer diagnostic techniques (spectral domain OCT, micoperimetry) to improve patient selection.